Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.53 |
| ▸ | NPC1 | O15118 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17107274 | 0.84 | RAB9A (0.62) | RAB9ANPC1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL17107276 | 0.84 | RAB9A (0.62) | RAB9ANPC1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL17107129 | 0.83 | RAB9A (0.71) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17107128 | 0.83 | RAB9A (0.71) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17133129 | 0.81 | RAB9A (0.62) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17107273 | 0.79 | ALOX5 (0.67) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17107275 | 0.79 | ALOX5 (0.67) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17107112 | 0.73 | RAB9A (0.61) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17132024 | 0.73 | RAB9A (0.61) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13592290 | 0.71 | KDM4E (0.39) | RAB9ANPC1ALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650369-B2 | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease | XAVIER UNIVERSITY OF LOUISIANA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650369-B2 | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease | XAVIER UNIVERSITY OF LOUISIANA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | XAVIER UNIVERSITY OF LOUISIANA | 2015-10-01 | — | — | US | disclosed |
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | XAVIER UNIVERSITY OF LOUISIANA | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | MKI67, MIF, NUDC | RAB9A 1305/4885NPC1 189/4885ALDH1A1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.